SEC Form 4 · accession 0001127602-18-005574
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gayle E Wilson
Director
Period of report
Feb 9, 2018
Accepted (ET)
Feb 13, 2018 · 5:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 9, 2018 | M | 60,000 | $26.615 | A | 182,258 | D | |
| Common StockF1 | Feb 9, 2018 | S | 60,000 | $77.918 | D | 122,258 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $26.615 | Feb 9, 2018 | M | 60,000 | D | — | May 8, 2018 | Common Stock | 60,000 | 0 | D |
Explanation of responses
- F1Sale prices reported for the transactions reported here range from $77.88 to $78.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F2Options vest 100% on the first anniversary date of the grant.